Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melinda K Lacy

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|July 14, 2018
Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN TrialsBoris Nogid, Melinda K Lacy, Micah Jacobs, et al.
The Annals of Pharmacotherapy|August 10, 2006
Doxycycline for community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infectionsMelinda K Carter, Vernessa A Ebers, Bachir K Younes, et al.
Journal of Clinical Microbiology|October 9, 2003
Effect of duplicate isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus on antibiogram dataRebecca T Horvat, Neil E Klutman, Melinda K Lacy, et al.
Journal of Clinical Microbiology|June 16, 2005
Nationwide antibiogram analysis using NCCLS M39-A guidelinesAntonia Zapantis, Melinda K Lacy, Rebecca T Horvat, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 21, 2024
Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPDWilliam Blake LeMaster, Corey J Witenko, Melinda K Lacy, et al.
Drugs - Real World Outcomes|May 27, 2021
Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)Charles R Sims, Adam M Bressler, Donald R Graham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2015
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortalityMelinda K Lacy, Martin E Stryjewski, Whedy Wang, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 8, 2026
Understanding Nebulizer Utilization by Patients and Healthcare Providers: A COPD Foundation Nebulizer Consortium Survey StudyKathryn H Melamed, Sergio Martinez, Lisa Cambridge, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|July 14, 2018
Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN TrialsBoris Nogid, Melinda K Lacy, Micah Jacobs, et al.
The Annals of Pharmacotherapy|August 10, 2006
Doxycycline for community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infectionsMelinda K Carter, Vernessa A Ebers, Bachir K Younes, et al.
Journal of Clinical Microbiology|October 9, 2003
Effect of duplicate isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus on antibiogram dataRebecca T Horvat, Neil E Klutman, Melinda K Lacy, et al.
Journal of Clinical Microbiology|June 16, 2005
Nationwide antibiogram analysis using NCCLS M39-A guidelinesAntonia Zapantis, Melinda K Lacy, Rebecca T Horvat, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 21, 2024
Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPDWilliam Blake LeMaster, Corey J Witenko, Melinda K Lacy, et al.
Drugs - Real World Outcomes|May 27, 2021
Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)Charles R Sims, Adam M Bressler, Donald R Graham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2015
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortalityMelinda K Lacy, Martin E Stryjewski, Whedy Wang, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 8, 2026
Understanding Nebulizer Utilization by Patients and Healthcare Providers: A COPD Foundation Nebulizer Consortium Survey StudyKathryn H Melamed, Sergio Martinez, Lisa Cambridge, et al.
Pageof 1